BIOMARKER:

Chr amplification(1q)

News alerts, weekly reports and conference planners

Chr amplification(1q)	Multiple Myeloma	Chr amplification(1q)	Multiple Myeloma	VRD Resistant: B - Late Trials VRD Resistant : B	VRD Resistant: B - Late Trials VRD Resistant : B
Chr amplification(1q)	Multiple Myeloma	Chr amplification(1q)	Multiple Myeloma	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3
Chr amplification(1q)	Multiple Myeloma	Chr amplification(1q)	Multiple Myeloma	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3
Chr amplification(1q)	Multiple Myeloma	Chr amplification(1q)	Multiple Myeloma	bortezomib Resistant: C3 – Early Trials bortezomib Resistant : C3	bortezomib Resistant: C3 – Early Trials bortezomib Resistant : C3
Chr amplification(1q)	Multiple Myeloma	Chr amplification(1q)	Multiple Myeloma	venetoclax Resistant: D – Preclinical venetoclax Resistant : D	venetoclax Resistant: D – Preclinical venetoclax Resistant : D

Associations